D. Sibbing

M. Hadamitzky, H. Ince, B. Merkely, 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction

M. Hadamitzky, J. Hausleiter, H. Schunkert, 2014, Thrombosis and Haemostasis.

A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel

A. Kastrati, A. Schömig, B. Baker, 2013, Platelets.

Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting

A. Kastrati, A. Schömig, D. Sibbing, 2013, Thrombosis and Haemostasis.

The impact of smoking on the antiplatelet action of clopidogrel in non‐ST‐elevation myocardial infarction patients: results from the ISAR‐REACT 4 platelet substudy

A. Kastrati, J. Mehilli, A. Schömig, 2012, Journal of thrombosis and haemostasis : JTH.

Periinterventionelle antithrombozytäre Therapie

D. Sibbing, S. Massberg, C. Schulz, 2012, Herz.

Predictors of antiplatelet response to prasugrel during maintenance treatment

M. Hadamitzky, H. Schunkert, A. Kastrati, 2015, Platelets.

Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention

H. Schunkert, A. Kastrati, B. Haller, 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

OP-EUPA180177 1..27

H. Crijns, J. Airaksinen, H. Bueno, 2018 .

LMU Munich: platelet inhibition novel aspects on platelet inhibition and function

D. Sibbing, S. Massberg, C. Schulz, 2018, Clinical Research in Cardiology.

Antithrombotic therapy for acute coronary syndrome: Past, present and future

K. Huber, D. Angiolillo, D. Sibbing, 2017, Thrombosis and Haemostasis.

A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI

M. Hadamitzky, J. Mehilli, F. Neumann, 2016, Thrombosis and Haemostasis.

Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting.

D. Sibbing, L. Gross, 2017, Interventional cardiology clinics.

Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?

D. Sibbing, D. Aradi, L. Gross, 2015, Thrombosis and Haemostasis.

Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study

A. Kastrati, D. Sibbing, K. Mayer, 2016, Platelets.

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.

M. Price, G. Stone, A. Kirtane, 2015, European heart journal.

Restoring platelet function in patients on P2Y12 receptor inhibitor treatment: still some issues to be solved!

D. Sibbing, S. Massberg, 2015, Circulation. Cardiovascular interventions.

ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?

D. Sibbing, D. Aradi, 2015, Thrombosis and Haemostasis.

Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis

J. Mega, B. Horne, Jeffrey L. Anderson, 2009 .

Randomized Comparison of Intensified and Standard P2Y12-Receptor-Inhibition Before Elective Percutaneous Coronary Intervention

A. Kastrati, J. Mehilli, F. Neumann, 2020, Circulation. Cardiovascular interventions.

Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.

H. Schunkert, A. Kastrati, A. Hapfelmeier, 2021, JAMA cardiology.

Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial

M. Hadamitzky, K. Huber, D. Sibbing, 2019, Journal of Thrombosis and Thrombolysis.

Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options

K. Schrör, D. Sibbing, D. Aradi, 2019, Thrombosis and Haemostasis.

BleedingandstentthrombosisonP 2 Y 12-inhibitors : collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

M. Price, G. Stone, A. Kirtane, 2015 .

Dual antiplatelet treatment after stenting: is longer better?

D. Sibbing, S. Massberg, 2014, The Lancet.

European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions.

J. Carroll, S. Kasner, B. Meier, 2021, European heart journal.

[2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)].

P. Seferovic, P. Jüni, V. Falk, 2019, Giornale italiano di cardiologia.

A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients

D. Sibbing, D. Aradi, A. Beivers, 2013, Thrombosis and Haemostasis.

There’s life in the old dog yet: Clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients

D. Sibbing, S. Massberg, Steffen Massberg, 2014, Thrombosis and Haemostasis.

Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome

D. Sibbing, S. Massberg, M. Orban, 2013, Hämostaseologie.

Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.

A. Kastrati, A. Schömig, D. Sibbing, 2007, The American journal of cardiology.

Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy.

C. Gieger, A. Walch, T. Meitinger, 2011, European heart journal.

Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials.

D. Sibbing, D. Aradi, V. Serebruany, 2013, International journal of cardiology.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

A. Kastrati, J. Mehilli, A. Schömig, 2010, Journal of thrombosis and haemostasis : JTH.

The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders

A. Kastrati, D. Sibbing, I. Bernlochner, 2011, Expert review of cardiovascular therapy.

Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention.

A. Kastrati, A. Schömig, I. Ott, 2008, European heart journal.

Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.

M. Hadamitzky, F. Neumann, B. Merkely, 2019, European heart journal.

Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction

M. Schwaiger, A. Kastrati, J. Mehilli, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.

J. Erdmann, H. Schunkert, N. Eriksson, 2019, Cardiovascular research.

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

M. Hadamitzky, A. Kastrati, A. Schömig, 2009, Thrombosis and Haemostasis.

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.

Deepak L. Bhatt, Sunil V. Rao, M. Price, 2013, Journal of the American College of Cardiology.

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial

M. Hadamitzky, P. Boekstegers, J. Mehilli, 2017, The Lancet.

De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention

D. Sibbing, D. Kupka, 2018, Korean circulation journal.

Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

H. Schunkert, M. Joner, A. Kastrati, 2020, Circulation.

High platelet reactivity and clinical outcome – Fact and fiction

A. Kastrati, D. Sibbing, I. Bernlochner, 2011, Thrombosis and Haemostasis.

Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry

A. Kastrati, A. Schömig, D. Sibbing, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.

A. Kastrati, J. Mehilli, A. Schömig, 2010, European heart journal.

Pharmacokinetics of clopidogrel in patients with stent thrombosis

A. Kastrati, A. Schömig, D. Sibbing, 2008, Journal of thrombosis and haemostasis : JTH.

Platelet function in clopidogrel-treated patients with acute coronary syndrome

A. Kastrati, A. Schömig, D. Sibbing, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel

A. Kastrati, A. Schömig, D. Sibbing, 2006, Journal of thrombosis and haemostasis : JTH.

Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease

G. Lemesle, D. Sibbing, E. Puymirat, 2018, Thrombosis and Haemostasis.

Patent foramen ovale with a riding vermicular thrombus causing paradoxical and massive pulmonary embolism.

D. Sibbing, P. Barthel, J. Gaa, 2006, European heart journal.

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy Introduction

Deepak L. Bhatt, F. Rutten, B. Lewis, 2021 .

Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.

H. Schunkert, M. Joner, A. Kastrati, 2020, Journal of the American College of Cardiology.

De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention

D. Sibbing, D. Kupka, 2018, Korean circulation journal.

Effect of genotype-guided strategy in East Asian vs. Caucasian patients after percutaneous coronary intervention: insight from the TAILOR-PCI trial

D. Sibbing, Y. Jeong, Hyun Kuk Kim, 2020, Journal of thoracic disease.

Coronary heart disease A double-blind , randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

A. Wieczorek, A. Kastrati, A. Schömig, 2007 .

Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system.

A. Kastrati, A. Schömig, D. Sibbing, 2009, American journal of clinical pathology.

Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy).

A. Kastrati, J. Mehilli, J. Hausleiter, 2016, Thrombosis research.

Current evidence for monitoring platelet reactivity in acute coronary syndrome: a plea for individualized antiplatelet treatment.

D. Sibbing, L. Bonello, D. Aradi, 2013, International journal of cardiology.

Influence of smoking on treatment with clopidogrel.

A. Kastrati, D. Sibbing, W. Hochholzer, 2012, JAMA.

Platelet Function Testing in Patients with Acute Coronary Syndrome

D. Sibbing, M. Orban, 2013, Journal of Cardiovascular Translational Research.

Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes

H. Schunkert, A. Kastrati, F. Neumann, 2020, Annals of Internal Medicine.

Thienopyridines and other ADP-receptor antagonists.

D. Sibbing, I. Bernlochner, 2012, Handbook of experimental pharmacology.

Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.

J. Mega, M. Sabatine, A. Kastrati, 2011, American heart journal.

De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature

D. Claassens, D. Sibbing, Daniel M. F. Claassens, 2020, Journal of clinical medicine.

Smoking and Outcomes Following Guided De-escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: A Substudy from the Randomized TROPICAL-ACS Trial.

M. Hadamitzky, K. Huber, J. Rieber, 2019, European heart journal. Cardiovascular pharmacotherapy.

CYP2C19 Genotyping in Percutaneous Coronary Intervention-Treated Patients: Ready for Prime Time?

D. Sibbing, L. Gross, 2018, JACC. Cardiovascular interventions.

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes

E. Antman, J. Mega, M. Price, 2015, Journal of Thrombosis and Thrombolysis.

No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting

A. Kastrati, J. Mehilli, A. Schömig, 2012, Circulation. Cardiovascular interventions.

SUPPLEMENTAL MATERIAL No Association of ABCB 1 C 3435 T Genotype with Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting

A. Kastrati, J. Mehilli, A. Schömig, 2012 .

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.

A. Kastrati, J. Eikelboom, G. Paré, 2011, Circulation. Cardiovascular interventions.

CYP2C19 in ACS Patients: Could Genotyping Have a Role in Medically Managed Patients or Beyond?

D. Sibbing, S. Massberg, L. Gross, 2016, Journal of the American College of Cardiology.

High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring

A. Kastrati, A. Schömig, D. Sibbing, 2013, Platelets.

Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.

H. Schunkert, M. Joner, A. Kastrati, 2021, Revista espanola de cardiologia.

Pharmacology: Inhibitors of P2Y 12

D. Sibbing, D. Aradi, L. Gross, 2017 .

International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies

Deepak L. Bhatt, M. Price, R. Mehran, 2017, Circulation.

Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock

J. Hausleiter, D. Sibbing, K. Laugwitz, 2011, Thrombosis and Haemostasis.

Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.

A. Kastrati, J. Mehilli, A. Schömig, 2011, American heart journal.

Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention

A. Kastrati, A. Schömig, I. Ott, 2009, Thrombosis and Haemostasis.

Comments on the 2018 ESC / EACTS Guidelines onMyocardial Revascularization

V. Falk, A. Kastrati, F. Neumann, 2022 .

A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta‐analysis

Yun Gi Kim, J. Suh, A. Kastrati, 2017, American heart journal.

Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?

D. Sibbing, S. Massberg, L. Gross, 2013, JACC. Cardiovascular interventions.

Platelet Reactivity and Early Outcomes after Transfemoral Aortic Valve Implantation

J. Mehilli, L. Holdt, D. Teupser, 2018, Thrombosis and Haemostasis.

Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.

A. Kastrati, J. Mehilli, A. Schömig, 2010, American heart journal.

Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors

A. Kastrati, J. Mehilli, A. Schömig, 2010, Thrombosis and Haemostasis.

A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity

H. Schunkert, A. Kastrati, J. Hausleiter, 2014, Thrombosis and Haemostasis.

2018 ESC/EACTS Guidelines on myocardial revascularization.

Volkmar Falk, Fernando Alfonso, Peter Jüni, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper.

T. Chao, L. Fauchier, T. Potpara, 2022, Thrombosis and haemostasis.

Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.

Adnan Kastrati, Albert Schömig, A. Kastrati, 2010, American heart journal.

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

Adnan Kastrati, Albert Schömig, A. Kastrati, 2009, Journal of the American College of Cardiology.

Smoking and Clopidogrel Response Revisited: Hemoglobin Levels Explaining the Smoker's Paradox.

D. Sibbing, L. Gross, 2016, JACC. Cardiovascular interventions.

Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor

M. Joner, A. Kastrati, J. Hausleiter, 2012, Platelets.

Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.

Munich, A. Kastrati, J. Mehilli, 2012, Journal of the American College of Cardiology.

Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients

A. Kastrati, A. Schömig, D. Sibbing, 2010, Thrombosis and Haemostasis.

CorrespondenceLetter to the EditorReply

A. Kastrati, D. Sibbing, N. Beckerath, 2009 .

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

Marco Valgimigli, Gregg W Stone, Matthew J Price, 2019, JACC. Cardiovascular interventions.

Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial

H. Schunkert, M. Joner, A. Kastrati, 2022, Clinical Research in Cardiology.

Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial.

H. Schunkert, A. Kastrati, D. Angiolillo, 2020, Journal of the American College of Cardiology.

Reply: Platelet Function and Genetic Testing in Patients Receiving Oral Anticoagulation and Antiplatelet Treatment: An Area of Unmet Need.

D. Angiolillo, D. Sibbing, 2019, JACC. Cardiovascular interventions.

Antiplatelet strategies in elderly people: still a long way to go

D. Sibbing, S. Massberg, 2016, The Lancet.

[2018 ESC/EACTS Guidelines on myocardial revascularization].

Volkmar Falk, Fernando Alfonso, Josef Niebauer, 2018, Kardiologia polska.

Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease.

Christoph Laske, Stefanie Dimmeler, Kimon Stamatelopoulos, 2015, Journal of the American College of Cardiology.

Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity

Stefan Brunner, J. Mehilli, L. Holdt, 2016, Platelets.

Direct oral anticoagulants and antiplatelet agents

D. Sibbing, M. Spannagl, Dirk Sibbing, 2013, Hämostaseologie.

European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.

B. Meier, D. Dudek, F. Gaita, 2018, European heart journal.

Antithrombotic Therapy after Percutaneous Coronary Intervention of Bifurcation Lesions.

F. Burzotta, G. Dangas, R. Mehran, 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.

D. Atar, C. Held, B. Lewis, 2022, European heart journal.

Spontaneous Coronary Artery Dissection: A Less-Is-More Approach Is Justified.

D. Sibbing, R. Hein, 2019, JACC. Cardiovascular interventions.

2018 ESC/EACTS Guidelines on myocardial revascularization.

P. Seferovic, P. Jüni, V. Falk, 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Diplopia on vorapaxar: An unexpected side effect emerging only at second glance

D. Sibbing, L. Gross, 2016, Thrombosis and Haemostasis.

Does Size Matter?: In Search of a Physiological Definition of Myocardial Atrophy

H. Schunkert, A. Kastrati, D. Sibbing, 2017 .

Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness

A. Wieczorek, A. Kastrati, A. Schömig, 2006, Thrombosis and Haemostasis.

Bleeding and Thrombosis Risk Matters One-Size-Fits-All Strategy of Platelet Inhibition?*

D. Sibbing, S. Massberg, L. Gross, 2013 .

A. Kastrati, J. Mehilli, A. Schömig, 2012, Journal of the American College of Cardiology.

Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

H. Thiele, A. Kastrati, J. Mehilli, 2020, European heart journal.

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart

J. Grapsa, J. Mehilli, E. Grove, 2021, European heart journal.

Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass.

D. Sibbing, S. Cassese, 2021, JACC. Cardiovascular interventions.

European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions.

B. Meier, D. Dudek, F. Gaita, 2021, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Platelet glycoprotein IIb/IIIa receptor antagonists: a guide to patient selection and optimal use

M. Seyfarth, D. Sibbing, P. Berger, 2008 .

TCT-747 Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis

M. Price, M. Valgimigli, D. Sibbing, 2012 .

Circulation: Cardiovascular Interventions

H. Schunkert, M. Joner, A. Kastrati, 2022 .

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Deepak L. Bhatt, F. Rutten, B. Lewis, 2020, European heart journal.

Very Late Stent Thrombosis 42 Months after Implantation of Sirolimus-Eluting Stent and Discontinuation of Antiplatelet Therapy

J. Pache, D. Sibbing, K. Laugwitz, 2009, Case reports in medicine.

Platelet Function Testing in Patients on Antiplatelet Medications

D. Sibbing, D. Aradi, L. Gross, 2016, Seminars in Thrombosis & Hemostasis.

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

A. Kastrati, J. Mehilli, A. Schömig, 2008, European heart journal.

Role of platelet function testing in clinical practice: current concepts and future perspectives.

A. Kastrati, D. Sibbing, R. Byrne, 2011, Current drug targets.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Deepak L. Bhatt, F. Rutten, B. Lewis, 2021, Revista espanola de cardiologia.

Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis

G. Lip, E. Grove, Á. Lanas, 2016, European heart journal.

Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications

F. Santilli, D. Sibbing, M. Abdelhamid, 2022, American journal of preventive cardiology.

P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate‐induced platelet activation and aggregation after administration of a single high dose of clopidogrel

A. Kastrati, A. Schömig, D. Sibbing, 2006, Journal of thrombosis and haemostasis : JTH.

P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes.

D. Angiolillo, D. Sibbing, L. Bonello, 2018, Circulation.

DEPTH P 2 Y 12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes Review of the Current Evidence

D. Angiolillo, D. Sibbing, L. Bonello, 2018 .

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Deepak L. Bhatt, M. Price, R. Becker, 2010, Journal of the American College of Cardiology.

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

H. Schunkert, M. Joner, A. Kastrati, 2022, Thrombosis and Haemostasis.

Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

A. Kastrati, J. Mehilli, D. Sibbing, 2013, Journal of the American College of Cardiology.

Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease

G. Lip, C. Baigent, A. Siegbahn, 2016, Thrombosis and Haemostasis.

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.

E. Grove, C. Patrono, C. Baigent, 2018, European heart journal.

The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Sidney C. Smith, M. Jeong, Seung‐Jung Park, 2020, Thrombosis and Haemostasis.

Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)

A. Kastrati, J. Mehilli, D. Sibbing, 2015, BioMed research international.

OP-EHEA210395_online 4013..4028

B. Lewis, V. Aboyans, L. Mazzolai, 2021 .

P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis

D. Sibbing, D. Kupka, 2018, Expert opinion on drug metabolism & toxicology.

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy

A. Kastrati, J. Mehilli, A. Schömig, 2010, Journal of thrombosis and haemostasis : JTH.

A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.

Adnan Kastrati, Albert Schömig, Melchior Seyfarth, 2008, Journal of the American College of Cardiology.

Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis.

M. Price, M. Valgimigli, D. Sibbing, 2013, International journal of cardiology.

Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial

M. Hadamitzky, J. Mehilli, F. Neumann, 2018, European heart journal.

Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation

H. Schunkert, A. Kastrati, J. Mehilli, 2014, Thrombosis and Haemostasis.

A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment.

A. Kastrati, J. Mehilli, M. Seyfarth, 2010, Journal of the American College of Cardiology.

High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry

H. Schunkert, A. Kastrati, G. Ndrepepa, 2023, Clinical Research in Cardiology.

Reply: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation.

A. Kastrati, J. Mehilli, D. Sibbing, 2015, Journal of the American College of Cardiology.

Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study

K. Huber, D. Sibbing, T. Geisler, 2019, Thrombosis and Haemostasis.

European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.

B. Meier, D. Dudek, F. Gaita, 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study.

A. Kastrati, J. Mehilli, D. Sibbing, 2014, American heart journal.

Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy

M. Hadamitzky, M. Gawaz, D. Sibbing, 2018, Thrombosis and Haemostasis.

The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry.

M. Hadamitzky, H. Schunkert, A. Kastrati, 2015, Thrombosis research.

Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy

M. Hadamitzky, K. Huber, D. Sibbing, 2019, Thrombosis and Haemostasis.

De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis

M. D. del Aguila, A. Yakovlev, D. Angiolillo, 2019, Journal of Thrombosis and Thrombolysis.

Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.

H. Schunkert, A. Kastrati, F. Neumann, 2020, JACC. Cardiovascular interventions.

Intracardiac right ventricular metastatic tumor of malignant T-cell lymphoma.

D. Sibbing, P. Barthel, J. Gaa, 2007, International journal of cardiology.

Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI).

D. Sibbing, M. Grabowski, P. Scisło, 2015, Thrombosis research.

European Perspectives in Cardiology European Perspectives in Cardiology

D. Sibbing, 2010 .

Response to Letter Regarding Article, “Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement”

Adnan Kastrati, Tibor Schuster, Albert Schömig, 2010 .

Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment

S. Steinhubl, A. Kastrati, J. Mehilli, 2010, Thrombosis and Haemostasis.

Long-term outcome of patients with severe biventricular heart failure and severe mitral regurgitation after percutaneous edge-to-edge mitral valve repair.

P. Boekstegers, J. Mehilli, J. Hausleiter, 2015, Journal of interventional cardiology.

Platelet CCL5 links acute coronary syndrome and vascular inflammation

D. Sibbing, C. Schulz, 2014, Thrombosis and Haemostasis.

Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.

Hyo‐Soo Kim, Hyun-Jae Kang, D. Claassens, 2023, European heart journal.

Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial

H. Schunkert, M. Joner, A. Kastrati, 2022, Circulation. Cardiovascular interventions.

Platelet hyperreactivity and stent thrombosis in patients undergoing coronary stenting.

D. Sibbing, K. Mayer, 2012, Current vascular pharmacology.

Management of Myocardial Revascularization in Patients With Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation

H. Schunkert, M. Joner, A. Kastrati, 2022, Circulation. Cardiovascular interventions.

Candidate gene studies in focal dystonia

I. König, A. Ziegler, M. Vidailhet, 2003, Neurology.

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Deepak L. Bhatt, P. Serruys, M. Krucoff, 2023, Circulation.

Copper genes are not implicated in the pathogenesis of focal dystonia.

W. Poewe, F. Asmus, T. Gasser, 2002, Neurology.

Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.

H. Schunkert, A. Kastrati, D. Sibbing, 2014, Journal of the American College of Cardiology.

Clinical use of clopidogrel.

D. Sibbing, R. Byrne, N. Sarafoff, 2012, Current pharmaceutical design.

Abstract 28: A Prospective and Randomized Trial to Compare a Left Ventricular Assist Device (Impella LP2.5) With IABP in Patients With Cardiogenic Shock by Acute Myocardial Infarction: The ISAR-SHOCK Trial

A. Kastrati, M. Seyfarth, A. Schömig, 2007 .

Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.

H. Schunkert, M. Joner, A. Kastrati, 2021, JACC: Cardiovascular Interventions.

Cytochrome P 450 2 C 19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

A. Kastrati, J. Mehilli, A. Schömig, 2009 .

Acute, periprocedural and longterm antithrombotic therapy in older adults.

C. Patrono, B. Gigante, J. Morais, 2022, European heart journal.

Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy

H. Schunkert, A. Kastrati, D. Angiolillo, 2022, Arteriosclerosis, thrombosis, and vascular biology.

Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.

H. Schunkert, M. Joner, A. Kastrati, 2021, JAMA cardiology.

De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

M. Valgimigli, J. T. ten Berg, D. Sibbing, 2023, Nature Reviews Cardiology.

Reply: Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry.

H. Schunkert, A. Kastrati, D. Sibbing, 2015, Journal of the American College of Cardiology.

Restoring platelet function in patients on P2Y12 receptor inhibitor treatment: still some issues to be solved!

D. Sibbing, S. Massberg, 2015, Circulation. Cardiovascular interventions.

A. Kastrati, J. Mehilli, A. Schömig, 2012, Journal of the American College of Cardiology.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

A. Kastrati, J. Mehilli, A. Schömig, 2011, European heart journal.

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

E. Antman, J. Mega, B. Horne, 2017 .

Should Genetic Testing Be Done in All Patients Treated With Clopidogrel and Undergoing Percutaneous Coronary Intervention? Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting

A. Kastrati, D. Sibbing, I. Bernlochner, 2011 .

Munich, A. Kastrati, J. Mehilli, 2012, Journal of the American College of Cardiology.

European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.

B. Meier, D. Dudek, F. Gaita, 2018, European heart journal.

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.

Li Zhang, A. Kastrati, D. Sibbing, 2008, European heart journal.

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

A. Kastrati, J. Mehilli, A. Schömig, 2009, Journal of the American College of Cardiology.

Patent foramen ovale with a riding vermicular thrombus causing paradoxical and massive pulmonary embolism.

D. Sibbing, P. Barthel, J. Gaa, 2006, European heart journal.

No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting

A. Kastrati, J. Mehilli, A. Schömig, 2012, Circulation. Cardiovascular interventions.

Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system.

A. Kastrati, A. Schömig, D. Sibbing, 2009, American journal of clinical pathology.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Deepak L. Bhatt, F. Rutten, B. Lewis, 2021, Revista espanola de cardiologia.

Body mass index and efﬁcacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes

G. Ndrepepa, D. Angiolillo, D. Sibbing, 2022 .

Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.

D. Angiolillo, D. Sibbing, P. Vranckx, 2024, Circulation.

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.

D. Angiolillo, J. T. ten Berg, D. Sibbing, 2021, European heart journal.

2018 ESC/EACTS Guidelines on myocardial revascularization.

V. Falk, A. Kastrati, F. Neumann, 2019, EuroIntervention.

Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.

H. Schunkert, A. Kastrati, J. Mehilli, 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Reply: Platelet Function and Genetic Testing in Patients Receiving Oral Anticoagulation and Antiplatelet Treatment: An Area of Unmet Need.

D. Angiolillo, D. Sibbing, 2019, JACC. Cardiovascular interventions.